The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place.
Government is expanding prescription coverage for long-acting muscarinic antagonist (LAMAs) inhalers, used in the treatment of Chronic Obstructive Pulmonary Disease. The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place. This will ensure NLPDP beneficiaries have timely access to these inhalers for the treatment of their COPD.
Trans Canada Highway near Clarenville is impassable due to a serious collision
Daylight Savings Time ends this weekend, clocks go back one hour
St. John's man wanted by Deer Lake RCMP
Local MHA says former hospital in Corner Brook could be used for those needing acute care
Opposition leader says the Stephenville food bank was forced to reduce hamper sizes just to stay operational
